메뉴 건너뛰기




Volumn 101, Issue 1, 2017, Pages 35-38

Clinical Development of Cell Therapies: Setting the Stage for Academic Success

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL THERAPY; HUMAN; IMMUNOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REGULATORY T LYMPHOCYTE; ANIMAL; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); HEALTH SERVICE; PROCEDURES; TRANSLATIONAL RESEARCH;

EID: 85005938334     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.523     Document Type: Article
Times cited : (16)

References (6)
  • 1
    • 84896697076 scopus 로고    scopus 로고
    • Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells
    • Landwehr-Kenzel, S. et al. Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells. Am. J. Transplant. 14, 594–606 (2014).
    • (2014) Am. J. Transplant. , vol.14 , pp. 594-606
    • Landwehr-Kenzel, S.1
  • 2
    • 84865598850 scopus 로고    scopus 로고
    • Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells
    • Siepert, A. et al. Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. Am. J. Transplant. 12, 2384–2394 (2012).
    • (2012) Am. J. Transplant. , vol.12 , pp. 2384-2394
    • Siepert, A.1
  • 3
    • 84897116999 scopus 로고    scopus 로고
    • Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning
    • Juvet, S.C., Whatcott, A.G., Bushell, A.R. & Wood, K.J. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am. J. Transplant. 14, 750–763 (2014).
    • (2014) Am. J. Transplant. , vol.14 , pp. 750-763
    • Juvet, S.C.1    Whatcott, A.G.2    Bushell, A.R.3    Wood, K.J.4
  • 4
    • 84875476872 scopus 로고    scopus 로고
    • Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs
    • Abou-El-Enein, M. et al. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy 15, 362–383 (2013).
    • (2013) Cytotherapy , vol.15 , pp. 362-383
    • Abou-El-Enein, M.1
  • 6
    • 85010085251 scopus 로고    scopus 로고
    • Strategies for derisking translational processes for biomedical technologies
    • &,); e-pub ahead of print
    • Abou-El-Enein, M., Duda, G.N., Gruskin, E.A. & Grainger, D.W. Strategies for derisking translational processes for biomedical technologies. Trends Biotechnol. (2016); e-pub ahead of print.
    • (2016) Trends Biotechnol.
    • Abou-El-Enein, M.1    Duda, G.N.2    Gruskin, E.A.3    Grainger, D.W.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.